|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
With Johnson & Johnson deal, Elan's on much better financial footing -- even if bapineuzumab's a bust.
Debra Borchardt and Liz Trotta break down today's market. Guests include Adam Feurestein and Jonathon Corpina.
Here's what Jim Cramer's had to say lately about some of the stocks in today's news.
Elan announces a $1.5 billion investment by J&J wherein it will take over Elan's Alzheimer's unit and assume an 18.4% stake in the company.
The trading panel debated the impact of lower oil prices on the market.
Biogen received the rights to commercialize Acorda's multiple sclerosis drug outside of the U.S.
Biogen Idec reports that a tenth multiple sclerosis patient being treated with Tysabri was diagnosed with a serious brain infection.
Monday's early headlines include Bernard Madoff's sentencing, the head of the White House Council of Economic Advisors turning more positive on the economy, and reports that UBS is close to settling a tax-related dispute with the U.S.
The Swiss drugmaker is reportedly in talks to talks to buy certain operations from Ireland's Elan.
A quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.
Strategic talks were held last month between Irish drugmaker Elan and Bristol-Myers Squibb, but they broke down in the early stages, a report says.
Biogen Idec is the market leader in mulitiple sclerosis treatments, but oral drug rivals are turning up the pressure.
Gilead Sciences said its first-quarter revenue surged 22% from a year earlier as product sales reached a record high of $1.45 billion.
Biogen Idec reports a 27% increase in adjusted first-quarter earnings, but sales of its multiple sclerosis drug Tysabri don't meet estimates.
Biogen's expected to report a solid quarter, leaving investors more likely to focus on Tysabri data and M&A news.
Genentech says it is voluntarily withdrawing its psoriasis drug Raptiva from the U.S. market because of safety concerns.
Elan and Wyeth are eliminating the highest dose of an Alzheimer's drug from two phase III studies after independent safety monitors concluded patients were at risk for developing swelling of the brain.
Biogen meets with investors to pitch its research pipeline and stifle worries that its leading position in the multiple sclerosis treatment market is vulnerable to competition.
Notes from the Cowen and Co. Annual Health Care Conference in Boston.
Readers write in about Amgen, phase III trial upsets, Xoma and Elan, and Geron investors go wild.
Hewlett-Packard plans to create 500 jobs in Ireland over the next 12 months as the tech firm boosts its lucrative services business.
Genentech explains to investors and analysts why Roche's hostile tender offer is too low.
The Irish drugmaker said it plans to postpone biologics manufacturing and will realign the research and development operations within its biopharmaceutical business.
Researchers know of a protein that seems to play a key role in causing Alzheimer's disease. But why does this protein reside in the brain in the first place?
Elan reported fourth-quarter profit of $169.5 million, or 36 cents a share, as sales of multiple sclerosis drug Tysabri soared.
Biogen Idec shares are falling after the company reported weaker-than-expected sales of its multiple sclerosis drug Tysabri and cut the drug's long-term sales outlook.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.